Format
Sort by

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 112

1.

FDG-PET imaging in Merkel cell carcinoma - value of head-to-toe scan.

Golan H, Volkov O, Linchinsky O, Melloul M.

Nucl Med Rev Cent East Eur. 2005;8(2):135-6.

PMID:
16437401
2.

Merkel cell carcinoma: Is there a role for 2-deoxy-2-[f-18]fluoro-D-glucose-positron emission tomography/computed tomography?

Iagaru A, Quon A, McDougall IR, Gambhir SS.

Mol Imaging Biol. 2006 Jul-Aug;8(4):212-7.

PMID:
16724293
3.

Merkel cell carcinoma: two case reports focusing on the role of fluorodeoxyglucose positron emission tomography imaging in staging and surveillance.

Yao M, Smith RB, Hoffman HT, Funk GF, Graham MM, Buatti JM.

Am J Clin Oncol. 2005 Apr;28(2):205-10.

PMID:
15803018
4.

Comparison of 18F-FDG PET/CT and 111In pentetreotide scan for detection of Merkel cell carcinoma.

Lu Y, Fleming SE, Fields RC, Coit DG, Carrasquillo JA.

Clin Nucl Med. 2012 Aug;37(8):759-62. doi: 10.1097/RLU.0b013e31825ae8e7.

PMID:
22785503
5.
6.

Whole body 18F-FDG PET/CT imaging in the detection of primary tumours in patients with a metastatic carcinoma of unknown origin.

Kaya AO, Coskun U, Unlu M, Akdemir UO, Ozdemir NY, Zengin N, Benekli M, Yildiz R, Yaman E, Ozturk B, Gumus M, Uner A, Yamac D, Ucgul E, Buyukberber S.

Asian Pac J Cancer Prev. 2008 Oct-Dec;9(4):683-6.

7.

The impact of (18)F-FDG PET-CT scanning for staging and management of Merkel cell carcinoma: results from Westmead Hospital, Sydney, Australia.

Concannon R, Larcos GS, Veness M.

J Am Acad Dermatol. 2010 Jan;62(1):76-84. doi: 10.1016/j.jaad.2009.06.021.

PMID:
20082888
8.

Scanning with 18F-FDG-PET/CT for detection of pelvic nodal involvement in inguinal node-positive penile carcinoma.

Graafland NM, Leijte JA, Valdés Olmos RA, Hoefnagel CA, Teertstra HJ, Horenblas S.

Eur Urol. 2009 Aug;56(2):339-45. doi: 10.1016/j.eururo.2009.05.016. Epub 2009 May 19.

PMID:
19477581
9.

18F-fluorodeoxyglucose positron emission tomography-computed tomography imaging in the management of Merkel cell carcinoma: a single-institution retrospective study.

Ibrahim SF, Ahronowitz I, McCalmont TH, Hernandez Pampaloni M, Ryan JL, Yu SS.

Dermatol Surg. 2013 Sep;39(9):1323-33. doi: 10.1111/dsu.12246. Epub 2013 Jun 18.

PMID:
23777452
10.

The value of 18F-FDG PET in the detection of stage M0 carcinoma of the nasopharynx.

Yen TC, Chang JT, Ng SH, Chang YC, Chan SC, Lin KJ, Lin WJ, Fu YK, Lin CY.

J Nucl Med. 2005 Mar;46(3):405-10.

11.
12.

Evaluation of head and neck cancer with 18F-FDG PET: a comparison with conventional methods.

Kresnik E, Mikosch P, Gallowitsch HJ, Kogler D, Wiesser S, Heinisch M, Unterweger O, Raunik W, Kumnig G, Gomez I, Grünbacher G, Lind P.

Eur J Nucl Med. 2001 Jul;28(7):816-21.

PMID:
11504077
13.

Detection of unknown primary tumours and distant metastases in patients with cervical metastases: value of FDG-PET versus conventional modalities.

Regelink G, Brouwer J, de Bree R, Pruim J, van der Laan BF, Vaalburg W, Hoekstra OS, Comans EF, Vissink A, Leemans CR, Roodenburg JL.

Eur J Nucl Med Mol Imaging. 2002 Aug;29(8):1024-30. Epub 2002 May 4.

PMID:
12173016
14.

Positron emission imaging of head and neck cancer, including thyroid carcinoma.

Schöder H, Yeung HW.

Semin Nucl Med. 2004 Jul;34(3):180-97. Review.

PMID:
15202100
15.

The value of 18F-fluorodeoxyglucose positron emission tomography/computed tomography in carcinoma of an unknown primary: diagnosis and follow-up.

Yapar Z, Kibar M, Yapar AF, Paydas S, Reyhan M, Kara O, Buyukdereli G, Aydin M, Kelle AP, Unal I, Disel U, Yavuz S, Sahin B, Erkisi M.

Nucl Med Commun. 2010 Jan;31(1):59-66. doi: 10.1097/MNM.0b013e328332b340.

PMID:
19952921
16.

Evaluation of delayed 18F-FDG PET in differential diagnosis for malignant soft-tissue tumors.

Hamada K, Tomita Y, Ueda T, Enomoto K, Kakunaga S, Myoui A, Higuchi I, Yoshikawa H, Hatazawa J.

Ann Nucl Med. 2006 Dec;20(10):671-5.

PMID:
17385305
17.

Role of 18F-FDG PET in detecting primary site in the patient with primary unknown carcinoma.

Yabuki K, Tsukuda M, Horiuchi C, Taguchi T, Nishimura G.

Eur Arch Otorhinolaryngol. 2010 Nov;267(11):1785-92. doi: 10.1007/s00405-010-1371-3. Epub 2010 Sep 3.

PMID:
20814690
18.

Role of 2-deoxy-2-[F-18] fluoro-D-glucose positron emission tomography in the management of bone and soft-tissue metastases.

Yanagawa T, Shinozaki T, Iizuka Y, Takagishi K, Watanabe H.

J Bone Joint Surg Br. 2010 Mar;92(3):419-23. doi: 10.1302/0301-620X.92B3.23131.

PMID:
20190315
19.

Positron emission tomography for prostate, bladder, and renal cancer.

Schöder H, Larson SM.

Semin Nucl Med. 2004 Oct;34(4):274-92. Review.

PMID:
15493005
20.

Is there a role for fluorodeoxyglucose positron emission tomography/computed tomography in cytologically indeterminate thyroid nodules?

Hales NW, Krempl GA, Medina JE.

Am J Otolaryngol. 2008 Mar-Apr;29(2):113-8. doi: 10.1016/j.amjoto.2007.04.006.

PMID:
18314022
Items per page

Supplemental Content

Write to the Help Desk